Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer
Rebecca A. Gallego(Pfizer (United States)), Sajiv K. Nair(Pfizer (United States)), Thomas Knauber(Pfizer (United States)), William Farrell(Pfizer (United States)), John Braganza(Pfizer (United States)), Jamison B. Tuttle(Pfizer (United States)), Louise Bernier(Pfizer (United States)), Julie Cianfrogna(Pfizer (United States)), Mark A. Moen(Pfizer (United States)), Michele McTigue(Pfizer (United States)), Anne‐Marie Dechert‐Schmitt(Pfizer (United States)), Michael R. Collins(Pfizer (United States)), Beth C. Vetelino(Pfizer (United States)), Ted W. Johnson(WorldFish), Joseph W. Tucker(Boston University), Matthew Del Bel(Pfizer (United States)), Nicole Grable(Pfizer (United States)), Richard P. Loach(Pfizer (United States)), Zecheng Chen(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Jean Matthews(Pfizer (United States)), Sergei Timofeevski(Pfizer (United States)), Mehran Jalaie(Pfizer (United States)), Neal W. Sach(Pfizer (United States)), Nichol Miller(Pfizer (United States)), Omar Ahmad(Massachusetts Institute of Technology), Rob Kania(Pfizer (United States)), Cinthia Costa Jones(Pfizer (United States)), Allison Rohner(Pfizer (United States)), Joyann S. Donaldson(Pfizer (United States)), Sujin Cho-Schultz(Pfizer (United States)), Mark Niosi(Pfizer (United States)), Dahui Zhou(Pfizer (United States)), Rhys Jones(Pfizer (United States)), Ciarán N. Cronin(Pfizer (United States)), Andrew R. Nager(Pfizer (United States)), Scott P. France(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sébastien Monfette(Pfizer (United States)), Simon Berritt(Pfizer (United States)), Klaus Dress(Pfizer (United States)), Hud Risley(Pfizer (United States)), Peter Morse(Communities In Schools of Orange County), Eric F. Johnson(Pfizer (United States)), Lei Zhang(Pfizer (United States)), Ru Zhou(University of British Columbia), Mingying He(Pfizer (United States)), Carl Davis(Pfizer (United States)), Michael Maestre(Pfizer (United States)), Jennifer Lafontaine(Pfizer (United States)), Paul Richardson(Pfizer (United States))
Cited by 19
Related Papers
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|770